Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.68 |
| ▸ | PDE6C | P51160 | 2/20 | 0.58 |
| ▸ | PDE6D | O43924 | 1/20 | 0.58 |
| ▸ | PDE6A | P16499 | 1/20 | 0.58 |
| ▸ | PDE6G | P18545 | 1/20 | 0.58 |
| ▸ | PDE6B | P35913 | 1/20 | 0.58 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.58 |
| ▸ | PDE2A | O00408 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787907 | 0.92 | PDE5A (0.58) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7796215 | 0.90 | PDE5A (0.55) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7492921 | 0.87 | PDE5A (0.73) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7503454 | 0.87 | PDE5A (0.72) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7503470 | 0.87 | PDE5A (0.72) | PDE5APDE6CPDE6DPDE6APDE6G | |
| Hydrochloric Acid SCHEMBL6593977 | 0.81 | PDE5A (1.00) | PDE5APDE2A | |
| SCHEMBL7503460 | 0.81 | PDE5A (0.64) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7498058 | 0.79 | PDE5A (0.62) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7797372 | 0.79 | PDE5A (0.76) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL7503452 | 0.78 | PDE5A (0.71) | PDE5APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | PDE5A 2260/4885PDE6C 3960/4885PDE6D 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.